ScoreWhy is ImmunityBio, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate -195.50% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -38.35
2
With a growth in Net Profit of 921.54%, the company declared Outstanding results in Mar 26
- The company has declared positive results for the last 8 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD -294.4 MM
- NET PROFIT(HY) Higher at USD -192.95 MM
- DEBTORS TURNOVER RATIO(HY) Highest at 4.64 times
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 159.15%, its profits have risen by 25.7%
4
Majority shareholders : Mutual Funds
5
Market Beating Performance
- The stock has generated a return of 159.15% in the last 1 year, much higher than market (S&P 500) returns of 25.41%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to ImmunityBio, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is ImmunityBio, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
ImmunityBio, Inc.
159.15%
0.17
104.41%
S&P 500
25.41%
1.92
13.25%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
157.94%
EBIT Growth (5y)
-195.50%
EBIT to Interest (avg)
-38.35
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.23
Sales to Capital Employed (avg)
0.11
Tax Ratio
0.06%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
19.93%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-15.16
EV to EBIT
-31.86
EV to EBITDA
-33.92
EV to Capital Employed
120.47
EV to Sales
72.00
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-378.14%
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend27What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -294.4 MM
NET PROFIT(HY)
Higher at USD -192.95 MM
DEBTORS TURNOVER RATIO(HY)
Highest at 4.64 times
NET SALES(Q)
Highest at USD 44.21 MM
OPERATING PROFIT MARGIN(Q)
Highest at -147.97 %
RAW MATERIAL COST(Y)
Fallen by -17.33% (YoY
CASH AND EQV(HY)
Highest at USD 623.7 MM
-4What is not working for the Company
DEBT-EQUITY RATIO
(HY)
Highest at -85.49 %
PRE-TAX PROFIT(Q)
Lowest at USD -101.86 MM
NET PROFIT(Q)
Lowest at USD -101.85 MM
EPS(Q)
Lowest at USD -0.62
Here's what is working for ImmunityBio, Inc.
Operating Cash Flow
Highest at USD -294.4 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
Highest at USD 44.21 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Net Sales
At USD 44.21 MM has Grown at 56.08%
over average net sales of the previous four periods of USD 28.32 MMMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Operating Profit Margin
Highest at -147.97 % and Grown
In each period in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Debtors Turnover Ratio
Highest at 4.64 times and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Cash and Eqv
Highest at USD 623.7 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Raw Material Cost
Fallen by -17.33% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at USD 4.38 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (USD MM)
Here's what is not working for ImmunityBio, Inc.
Pre-Tax Profit
Lowest at USD -101.86 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (USD MM)
Net Profit
Lowest at USD -101.85 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
EPS
Lowest at USD -0.62
in the last five periodsMOJO Watch
Declining profitability; company has created lower earnings for shareholders
EPS (USD)
Debt-Equity Ratio
Highest at -85.49 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
